Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. VitalConnect brings in $25m
Wearable biometric diagnostic patch company VitalConnect said yesterday it raised a total of $25 million through the closure of a loan facility and an extended Series B financing round to support the commercialization of its HealthPatch MD and VitalPatch biosensors.
The company said it closed a term loan facility for $17.5 with Perceptive Advisors, with $10 million funded yesterday at its initial closing. Armentum Partners acted as a financial advisor to VitalConnect for the rounds. Read more
4. Insulet touts new data showing reduced A1c levels with Omnipod system | American Diabetes Assn. 2016 Scientific Sessions
Insulet touted the publication of new data supporting the benefits of its Omnipod insulin management system, with data supporting the systems’ efficacy at controlling blood glucose levels in patients switching from daily injections or tubed insulin pumps.
Data from the company’s multi-center retrospective study was used in 2 online publications in the Journal of Diabetes Science, Insulet said. Read more
3. Titan Spine touts implant warranty program
Titan Spine said yesterday it is expanding its spinal device warranty to include free replacement if its Endoskeleton interbody fusion devices delaminate or generate particulate debris during implantation.
The Mequon, Wisc.-based company said it amended its warranty, which it launched in 2014, based on its “confidence in its proprietary subtractive manufacturing process. Read more
2. Boston Scientific updates warnings for pelvic mesh products
Boston Scientific recently updated the directions for use and warnings for its pelvic mesh products, classifying the meshes as permanent implants and warning of complications related to removals.
The Marlborough, Mass.-based company added new precautions to the directions for the meshes, warning that that “regardless of the route of delivery,” the meshes have been associated with “erosion” which may require surgical removal. Read more
1. Terumo buys Sequent Medical for $280m
Terumo Corp. said today it picked up Sequent Medical, developer of the Web aneurysm embolization device, for $280 million.
The Web implant is made of a Nitinol mesh that is delivered in a “stent-like” manner and deployed into the pouch formed by an aneurysm in order to prevent blood from flowing in. Sequent won CE Mark approval for the Web system in 2010, and is running an FDA-approved investigational device exemption pivotal trial as it seeks U.S. clearance. Read more
